Cell transplantation and gene therapy in Parkinson's disease.
暂无分享,去创建一个
[1] A. Björklund,et al. Role of serotonin neurons in the induction of levodopa‐ and graft‐induced dyskinesias in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[2] R. Sidman,et al. Engraftable human neural stem cells respond to development cues, replace neurons, and express foreign genes , 1998, Nature Biotechnology.
[3] B. J. Hopper,et al. FETAL DOPAMINE-RICH MESENCEPHALIC GRAFTS IN PARKINSON'S DISEASE , 1988, The Lancet.
[4] E. Jauniaux,et al. The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro. , 2002, Brain research. Developmental brain research.
[5] J. Eberling,et al. Preclinical models of Parkinson's disease. , 2003, Current protocols in toxicology.
[6] Michael V. Green,et al. Persistent Dopamine Functions of Neurons Derived from Embryonic Stem Cells in a Rodent Model of Parkinson Disease , 2007, Stem cells.
[7] B J Hoffer,et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys , 1995, The Journal of comparative neurology.
[8] F. Bloom,et al. Formation of a functional adrenergic input to intraocular cerebellar grafts: ingrowth of inhibitory sympathetic fibers. , 1975, Journal of neurobiology.
[9] J. Fawcett,et al. A Glial Cell Line-Derived Neurotrophic Factor-Secreting Clone of the Schwann Cell Line SCTM41 Enhances Survival and Fiber Outgrowth from Embryonic Nigral Neurons Grafted to the Striatum and to the Lesioned Substantia Nigra , 1999, The Journal of Neuroscience.
[10] V. Mehta,et al. Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor , 1999 .
[11] L. Olson,et al. Locus coeruleus: fibre growth regulation in oculo. , 1976, Medical biology.
[12] S. Iversen,et al. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. II. Bilateral lesions , 1981, Brain Research.
[13] G. Paratcha,et al. GDNF and GFRα: a versatile molecular complex for developing neurons , 2008, Trends in Neurosciences.
[14] Philippe Hantraye,et al. Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy , 2009, The Journal of Neuroscience.
[15] S. Anisimov. Cell-based Therapeutic Approaches for Parkinson's Disease: Progress and Perspectives , 2009, Reviews in the neurosciences.
[16] H. Braak,et al. The Dual Hit Theory Revisited , 2009 .
[17] C. Holden. Neuroscience. Fetal cells again? , 2009, Science.
[18] S. Haber,et al. Survival and growth of fetal catecholamine neurons transplanted into primate brain , 1986, Brain Research Bulletin.
[19] A. Björklund,et al. Dopamine neuron systems in the brain: an update , 2007, Trends in Neurosciences.
[20] R. Barker,et al. Continuing trials of GDNF in Parkinson's disease , 2006, The Lancet Neurology.
[21] J. Takahashi,et al. Transplantation of embryonic stem cell-derived dopaminergic neurons in MPTP-treated monkeys. , 2009, Methods in molecular biology.
[22] A. Schapira,et al. Drug selection and timing of initiation of treatment in early Parkinson's disease , 2008, Annals of neurology.
[23] Shinya Yamanaka,et al. Generation of mouse-induced pluripotent stem cells with plasmid vectors , 2010, Nature Protocols.
[24] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[25] S. Dunnett,et al. Survival and Differentiation of Rat and Human Epidermal Growth Factor-Responsive Precursor Cells Following Grafting into the Lesioned Adult Central Nervous System , 1996, Experimental Neurology.
[26] O. Lindvall. Cerebral implantation in movement disorders: State of the art , 1999, Movement disorders : official journal of the Movement Disorder Society.
[27] M. Emborg,et al. Nonhuman primate models of Parkinson's disease. , 2007, ILAR journal.
[28] A. Björklund,et al. Neural transplantation for the treatment of Parkinson's disease , 2003, The Lancet Neurology.
[29] M. Pankratz,et al. Directed Neural Differentiation of Human Embryonic Stem Cells via an Obligated Primitive Anterior Stage , 2007, Stem cells.
[30] A. Björklund,et al. Cell replacement therapy: Helping the brain to repair itself , 2004 .
[31] William Jagust,et al. Convection-Enhanced Delivery of AAV Vector in Parkinsonian Monkeys; In Vivo Detection of Gene Expression and Restoration of Dopaminergic Function Using Pro-drug Approach , 2000, Experimental Neurology.
[32] L. Olson,et al. Seizures and related epileptiform activity in hippocampus transplanted to the anterior chamber of the eye I. Characterization of seizures, interictal spikes, and synchronous activity , 1977, Experimental Neurology.
[33] Dong-Wook Kim,et al. Efficient derivation of functional dopaminergic neurons from human embryonic stem cells on a large scale , 2008, Nature Protocols.
[34] A. Björklund,et al. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[35] G. Gerhardt,et al. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. , 2003, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[36] W. Freed,et al. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: Long‐term behavioral, biochemical, and histochemical studies , 1980, Annals of neurology.
[37] A. Björklund,et al. Identification of Dopaminergic Neurons of Nigral and Ventral Tegmental Area Subtypes in Grafts of Fetal Ventral Mesencephalon Based on Cell Morphology, Protein Expression, and Efferent Projections , 2005, The Journal of Neuroscience.
[38] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[39] R. Drucker-Colín,et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. , 1988, The New England journal of medicine.
[40] J. Kordower,et al. Gene therapy approaches for the treatment of Parkinson's disease. , 2007, Handbook of clinical neurology.
[41] Andrew King,et al. Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium , 2009, Acta Neuropathologica.
[42] M. Tuszynski,et al. Striatal delivery of CERE‐120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys , 2007, Movement disorders : official journal of the Movement Disorder Society.
[43] N. Blom,et al. In Vivo Protection of Nigral Dopamine Neurons by Lentiviral Gene Transfer of the Novel GDNF-Family Member Neublastin/Artemin , 2000, Molecular and Cellular Neuroscience.
[44] F. Gage,et al. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. , 1983, Acta physiologica Scandinavica. Supplementum.
[45] O. Isacson,et al. Recent advances in cell-based therapy for Parkinson disease. , 2008, Neurosurgical focus.
[46] J. Kordower,et al. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson’s disease , 2008, Neurobiology of Disease.
[47] C. Marsden,et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. , 1999, Brain : a journal of neurology.
[48] O. Isacson,et al. Transplanted dopamine neurons derived from primate ES cells preferentially innervate DARPP‐32 striatal progenitors within the graft , 2006, The European journal of neuroscience.
[49] R. Roth,et al. Fetal Dopamine Cell Survival after Transplantation Is Dramatically Improved at a Critical Donor Gestational Age in Nonhuman Primates , 1993, Experimental Neurology.
[50] L. Naldini. Lentiviruses as gene transfer agents for delivery to non-dividing cells. , 1998, Current opinion in biotechnology.
[51] W. Freed,et al. Derivation and characterization of neuronal precursors and dopaminergic neurons from human embryonic stem cells in vitro. , 2006, Methods in molecular biology.
[52] S. Jiao,et al. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection , 1997, Brain Research.
[53] D. E. Redmond,et al. Quantitative analysis of transgene protein, mRNA, and vector DNA following injection of an adenoviral vector harboring glial cell line-derived neurotrophic factor into the primate caudate nucleus. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[54] K. Hochedlinger,et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells , 2010, Nature Biotechnology.
[55] C. Svendsen,et al. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease , 2008, Experimental Neurology.
[56] R. M. Lightfoot,et al. Reprint: Six-Month Continuous Intraputamenal Infusion Toxicity Study of Recombinant Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (r-metHuGDNF) in Rhesus Monkeys , 2007, Toxicologic pathology.
[57] P. Brundin,et al. Induction of dopaminergic neurons from growth factor expanded neural stem/progenitor cell cultures derived from human first trimester forebrain , 2006, Brain Research Bulletin.
[58] T. Deacon,et al. Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat , 1996, Neuroscience.
[59] E. Mufson,et al. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies , 1996, The Journal of comparative neurology.
[60] J. Nutt,et al. Placebo influences on dyskinesia in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[61] Scott T. Grafton,et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.
[62] J. Utikal,et al. Induced Pluripotent Stem Cells Generated Without Viral Integration , 2008, Science.
[63] Ole Isacson,et al. CD15, CD24, and CD29 Define a Surface Biomarker Code for Neural Lineage Differentiation of Stem Cells , 2009, Stem cells.
[64] J. Obeso,et al. Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease , 2006, Nature Clinical Practice Neurology.
[65] S. Leurgans,et al. Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions , 2008, Movement disorders : official journal of the Movement Disorder Society.
[66] P. Greene. Cell-based therapies in Parkinson’s disease , 2009, Current neurology and neuroscience reports.
[67] N. Déglon,et al. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease , 2004, Neurobiology of Disease.
[68] Yoshiki Sasai,et al. Fluorescence‐Activated Cell Sorting–Based Purification of Embryonic Stem Cell–Derived Neural Precursors Averts Tumor Formation after Transplantation , 2006, Stem cells.
[69] R. McKay,et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease , 2002, Nature.
[70] Ornella Rimoldi,et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.
[71] A. Björklund. Cell therapy for Parkinson's disease: problems and prospects. , 2005, Novartis Foundation symposium.
[72] Y. Arsenijévic,et al. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. , 2000, Human gene therapy.
[73] R. Roth,et al. Fetal dopamine neural grafts: extended reversal of methylphenyltetrahydropyridine-induced parkinsonism in monkeys. , 1988, Progress in brain research.
[74] F. Gage,et al. Survival of intracerebrally grafted rat dopamine neurons previously cultured in vitro , 1985, Neuroscience Letters.
[75] Richard S. J. Frackowiak,et al. Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6‐L‐fluorodopa studies in two patients with putaminal implants , 1992, Annals of neurology.
[76] J. Sladek,et al. Embryonic mesencephalic and striatal co-grafts: Development of grafted dopamine neurons and functional recovery , 1990, Experimental Neurology.
[77] Richard S. J. Frackowiak,et al. Transplantation of fetal dopamine neurons in Parkinson's disease: One‐year clinical and neurophysiological observations in two patients with putaminal implants , 1992, Annals of neurology.
[78] J. Gracies,et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video‐based analysis , 2009, Movement disorders : official journal of the Movement Disorder Society.
[79] D. Trono,et al. Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.
[80] A. Björklund,et al. Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. , 1983, Acta physiologica Scandinavica. Supplementum.
[81] W. Rocca,et al. When does Parkinson disease start? , 2010, Archives of neurology.
[82] E. Bézard,et al. Preclinical development of gene therapy for Parkinson's disease , 2008, Experimental Neurology.
[83] R. Roth,et al. Intrastriatal Grafts from Multiple Donors do not Result in a Proportional Increase in Survival of Dopamine Neurons in Nonhuman Primates , 1998 .
[84] M. Hong,et al. Reconstruction of the Nigrostriatal Pathway by Simultaneous Intrastriatal and Intranigral Dopaminergic Transplants , 1996, The Journal of Neuroscience.
[85] M. Cenci,et al. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective , 2005, Brain Research Bulletin.
[86] David Eidelberg,et al. Subthalamic Glutamic Acid Decarboxylase Gene Therapy: Changes in Motor Function and Cortical Metabolism , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[87] A. Björklund,et al. Transgenic reporter mice as tools for studies of transplantability and connectivity of dopamine neuron precursors in fetal tissue grafts. , 2009, Progress in brain research.
[88] A. Björklund,et al. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector , 2002, Neuroreport.
[89] C. Olanow,et al. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease , 2006, Neurology.
[90] B. Hoffer,et al. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats , 1996, Cell and Tissue Research.
[91] Nobuyuki Itoh,et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. , 2005, The Journal of clinical investigation.
[92] D. Hilt,et al. Pharmacological Activities of Glial Cell Line-Derived Neurotrophic Factor (GDNF): Preclinical Development and Application to the Treatment of Parkinson's Disease , 1997, Experimental Neurology.
[93] R. Roth,et al. Cryopreservation, culture, and transplantation of human fetal mesencephalic tissue into monkeys. , 1988, Science.
[94] A. Björklund,et al. Regeneration of monoaminergic and cholinergic neurons in the mammalian central nervous system. , 1979, Physiological reviews.
[95] A. Bjo¨rklund,et al. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants , 1979, Brain Research.
[96] A. Björklund,et al. Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with co-implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor , 2005, Brain Research Bulletin.
[97] S B Dunnett,et al. Intracerebral grafting of neuronal cell suspensions. I. Introduction and general methods of preparation. , 1983, Acta physiologica Scandinavica. Supplementum.
[98] R. Bakay,et al. Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.
[99] A. Björklund,et al. Survival, growth and function of dopaminergic neurons grafted to the brain. , 1987, Progress in brain research.
[100] J. Powell,et al. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: a tyrosine hydroxylase immunocytochemical study , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[101] W. Freed,et al. Effect of dopamine agonists and antagonists on the electrical activity of substantia nigra neurons transplanted into the lateral ventricle of the rat , 2004, Experimental Brain Research.
[102] D. Maraganore,et al. Medical records documentation of constipation preceding Parkinson disease , 2009, Neurology.
[103] Martin Pera,et al. Transplantation of Human Embryonic Stem Cell–Derived Neural Progenitors Improves Behavioral Deficit in Parkinsonian Rats , 2004, Stem cells.
[104] C. Olanow,et al. Regulatable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself? , 2008, Experimental Neurology.
[105] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[106] B. Davidson,et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat , 1999, Gene Therapy.
[107] Clive N Svendsen,et al. A new method for the rapid and long term growth of human neural precursor cells , 1998, Journal of Neuroscience Methods.
[108] F. Gage,et al. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cells implanted in different brain sites , 1983 .
[109] A. Mahfoudi,et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. , 2002, Human gene therapy.
[110] W. Freed,et al. Dopaminergic Differentiation of Human Embryonic Stem Cells , 2004, Stem cells.
[111] A. Benabid,et al. Is deep brain stimulation neuroprotective if applied early in the course of PD? , 2008, Nature Clinical Practice Neurology.
[112] O. Isacson,et al. Markers and Methods for Cell Sorting of Human Embryonic Stem Cell‐Derived Neural Cell Populations , 2007, Stem cells.
[113] K. Hochedlinger,et al. Guidelines and techniques for the generation of induced pluripotent stem cells. , 2008, Cell stem cell.
[114] M. Tuszynski,et al. Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[115] Y. Samson,et al. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue , 2003, Movement disorders : official journal of the Movement Disorder Society.
[116] P. Césaro. The design of clinical trials for cell transplantation into the central nervous system , 2004 .
[117] Stanley Fahn,et al. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? , 2005, Journal of Neurology.
[118] R. Barker,et al. The future of cell therapies in the treatment of Parkinson's disease , 2007, Expert opinion on biological therapy.
[119] Yi Ai,et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects , 2003, The Journal of comparative neurology.
[120] A. Björklund,et al. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain , 2009, The European journal of neuroscience.
[121] E. Hol,et al. Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease. , 2007, Regenerative medicine.
[122] H. Nishino,et al. Mesencephalic Neural Stem (Progenitor) Cells Develop to Dopaminergic Neurons More Strongly in Dopamine-Depleted Striatum than in Intact Striatum , 2000, Experimental Neurology.
[123] G. Linazasoro. Cell Therapy for Parkinson's Disease: Only Young Onset Patients Allowed? Reflections about the Results of Recent Clinical Trials with Cell Therapy and the Progression of Parkinson's Disease , 2006, Cell transplantation.
[124] E. Snyder,et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes , 1999, Nature Biotechnology.
[125] C. Barcia,et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[126] R. Mandel,et al. Viral vectors for in vivo gene transfer in Parkinson's disease: Properties and clinical grade production , 2008, Experimental Neurology.
[127] B. Thiers. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .
[128] A. Storch,et al. Midbrain-derived neural stem cells: from basic science to therapeutic approaches , 2004, Cell and Tissue Research.
[129] A. Björklund,et al. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. , 2008, Progress in brain research.
[130] J. Kordower,et al. Propagation of host disease to grafted neurons: Accumulating evidence , 2009, Experimental Neurology.
[131] C. Svendsen,et al. Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy , 2007, Journal of Neuroscience Methods.
[132] Jia Luo,et al. Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model , 2002, Science.
[133] Richard Grondin,et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.
[134] Viswanathan Chandra,et al. One year survival and significant reversal of motor deficits in parkinsonian rats transplanted with hESC derived dopaminergic neurons. , 2008, Biochemical and biophysical research communications.
[135] A. Björklund,et al. Transplantation techniques for the study of regeneration in the central nervous system. , 1978, Progress in brain research.
[136] M. Emborg,et al. Preclinical assessment of stem cell therapies for neurological diseases. , 2009, ILAR journal.
[137] C. Svendsen,et al. Combining Growth Factors, Stem Cells, and Gene Therapy for the Aging Brain , 2004, Annals of the New York Academy of Sciences.
[138] O. Isacson,et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid , 2010, Molecular and Cellular Neuroscience.
[139] A. Björklund,et al. Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts , 1990, Nature.
[140] D. Cress. The need for regulatable vectors for gene therapy for Parkinson's disease , 2008, Experimental Neurology.
[141] R. Roth,et al. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys , 1990, Brain Research.
[142] R. Mandel,et al. Development of gene therapy for neurological disorders. , 2010, Discovery medicine.
[143] T. Schulz,et al. Directed neuronal differentiation of human embryonic stem cells , 2003, BMC Neuroscience.
[144] D. Jacobowitz,et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.
[145] J. Fawcett,et al. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. , 1996, Neuroreport.
[146] C D Marsden,et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.
[147] P. Ballard,et al. Parkinsonism Induced By 1-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson’s Disease , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[148] T. Ljungberg,et al. Electrophysiological and cytological studies of brain homografts in the anterior chamber of the eye: maturation of cerebellar cortex in oculo. , 1974, Brain research.
[149] R. Roth,et al. Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non‐human primate after overexpression of GDNF , 2009, The Journal of comparative neurology.
[150] M. Hong,et al. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells , 1998, Neuroscience.
[151] A. Dagher,et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.
[152] S. Gill,et al. GDNF delivery for Parkinson's disease. , 2007, Acta neurochirurgica. Supplement.
[153] T. Perlmann,et al. Neuronal cell replacement in Parkinson’s disease , 2009, Journal of internal medicine.
[154] J. Fawcett,et al. The Time Course of Loss of Dopaminergic Neurons and the Gliotic Reaction Surrounding Grafts of Embryonic Mesencephalon to the Striatum , 1996, Experimental Neurology.
[155] George Q. Daley,et al. Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.
[156] A. Björklund,et al. Serotonin Neuron Transplants Exacerbate l-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease , 2007, The Journal of Neuroscience.
[157] L. Olson,et al. Brain tissue transplanted to the anterior chamber of the eye: 2. Fluorescence histochemistry of immature catecholamine and 5-hydroxytryptamine neurons innervating the rat vas deferens , 2004, Cell and Tissue Research.
[158] D. Eidelberg,et al. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. , 2001, Human gene therapy.
[159] G. Gerhardt,et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. , 2007, Journal of neurosurgery.
[160] J. Ridet,et al. Lentiviral Vectors as a Gene Delivery System in the Mouse Midbrain: Cellular and Behavioral Improvements in a 6-OHDA Model of Parkinson's Disease Using GDNF , 2000, Experimental Neurology.
[161] S. Jiao,et al. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery , 1997, Neuroscience.
[162] V. Dhawan,et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease , 2001, Annals of neurology.
[163] R. Ridley,et al. Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.
[164] Joan Sacksteder. Bilateral Motor Improvement and Alteration of L-dopa Effect in Two Patients With Parkinsonʼs Disease Following Intrastriatal Transplantation of Foetal Ventral Mesencephalon , 1995 .
[165] Martin J. Aryee,et al. Epigenetic memory in induced pluripotent stem cells , 2010, Nature.
[166] Paul H Lerou,et al. Generation of human-induced pluripotent stem cells , 2008, Nature Protocols.
[167] S. Leff,et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[168] H. Braak,et al. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons , 2007, Acta Neuropathologica.
[169] O. Lindvall,et al. Stem cells in human neurodegenerative disorders--time for clinical translation? , 2010, The Journal of clinical investigation.
[170] C. Freed,et al. Noggin Enhances Dopamine Neuron Production from Human Embryonic Stem Cells and Improves Behavioral Outcome After Transplantation into Parkinsonian Rats , 2008, Stem cells.
[171] S. Fahn,et al. Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. , 2002, Neurosurgical focus.
[172] K. Hochedlinger,et al. Induced pluripotency of mouse and human somatic cells. , 2008, Cold Spring Harbor symposia on quantitative biology.
[173] H. Braak,et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen , 2003, Journal of Neural Transmission.
[174] P. Brundin,et al. Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic cell line—Studies in vitro and after intracerebral grafting in vivo , 2007, Molecular and Cellular Neuroscience.
[175] N. Déglon,et al. Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[176] S. Haber,et al. Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. , 1987, Progress in brain research.
[177] R. Barber,et al. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector , 2004, Neuroreport.
[178] R. Roth,et al. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF , 1987, Brain Research.
[179] A. Björklund,et al. Aberrant Sprouting and Downregulation of Tyrosine Hydroxylase in Lesioned Nigrostriatal Dopamine Neurons Induced by Long-Lasting Overexpression of Glial Cell Line Derived Neurotrophic Factor in the Striatum by Lentiviral Gene Transfer , 2002, Experimental Neurology.
[180] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[181] J. Mallet,et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[182] P R Sanberg,et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.
[183] C. Olanow,et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.
[184] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[185] L. Studer,et al. Induced pluripotent stem cell technology for the study of human disease , 2009, Nature Methods.
[186] H. Mizukami,et al. Neuroprotective Effects of Glial Cell Line-Derived Neurotrophic Factor Mediated by an Adeno-Associated Virus Vector in a Transgenic Animal Model of Amyotrophic Lateral Sclerosis , 2002, The Journal of Neuroscience.
[187] Pablo Menendez,et al. Human Induced Pluripotent Stem Cells Develop Teratoma More Efficiently and Faster Than Human Embryonic Stem Cells Regardless the Site of Injection , 2010, Stem cells.
[188] A. Björklund,et al. Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6‐hydroxydopamine lesioned adult rats , 1992, The Journal of comparative neurology.
[189] G. Gerhardt,et al. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. , 2006, Neurosurgical focus.
[190] Brian Spencer,et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.
[191] J. Utikal,et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. , 2007, Cell stem cell.
[192] Yang D. Teng,et al. Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells , 2007, Proceedings of the National Academy of Sciences.
[193] Rudolf Jaenisch,et al. Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.
[194] A. Björklund,et al. Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System , 2000, The Journal of Neuroscience.
[195] A. Bjo¨rklund,et al. Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival , 1976, Brain Research.
[196] A. Björklund,et al. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. , 2000, Progress in brain research.
[197] Rinne Uk. Dopamine agonists as primary treatment in Parkinson's disease. , 1987 .
[198] Su-Chun Zhang,et al. Directed Differentiation of Ventral Spinal Progenitors and Motor Neurons from Human Embryonic Stem Cells by Small Molecules , 2008, Stem cells.
[199] S. Yamanaka. Patient-specific pluripotent stem cells become even more accessible. , 2010, Cell stem cell.
[200] R. Sidman,et al. Segregation of Human Neural Stem Cells in the Developing Primate Forebrain , 2001, Science.
[201] A. Björklund,et al. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells , 2009, Proceedings of the National Academy of Sciences.
[202] Anders Björklund,et al. Cell transplantation in Parkinson's disease: how can we make it work? , 2005, Trends in Neurosciences.
[203] R. Roth,et al. Neural Stem Cells Implanted into MPTP-Treated Monkeys Increase the Size of Endogenous Tyrosine Hydroxylase-Positive Cells Found in the Striatum: A Return to Control Measures , 2005, Cell transplantation.
[204] O. Isacson,et al. Long‐Term Survival of Dopamine Neurons Derived from Parthenogenetic Primate Embryonic Stem Cells (Cyno‐1) After Transplantation , 2005, Stem cells.
[205] J. Kordower,et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease , 2007, Neurobiology of Disease.
[206] H. Braak,et al. Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology , 2006, Neuroscience Letters.
[207] Knut Stieger,et al. Immune responses to gene product of inducible promoters. , 2007, Current gene therapy.
[208] H. Braak,et al. Neuroanatomy and pathology of sporadic Parkinson's disease. , 2008, Advances in anatomy, embryology, and cell biology.
[209] O. Lindvall. Engineering neurons for Parkinson's disease , 1999, Nature Biotechnology.
[210] Guido Nikkhah,et al. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. II. Transplant-induced behavioral recovery , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[211] A. Björklund,et al. Fifty years of dopamine research , 2007, Trends in Neurosciences.
[212] K. Jellinger,et al. Formation and development of Lewy pathology: a critical update , 2009, Journal of Neurology.
[213] S. Dunnett,et al. Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model , 2005, The European journal of neuroscience.
[214] R. Roth,et al. Cellular repair in the parkinsonian nonhuman primate brain. , 2010, Rejuvenation research.
[215] P. Aebischer,et al. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy , 1998, Neuroreport.
[216] A. Björklund,et al. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path , 1976, Nature.
[217] C. Rosenblad,et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct , 2005, Experimental Neurology.
[218] Eric Jauniaux,et al. The differentiation potential of human foetal neuronal progenitor cells in vitro. , 2004, Brain research. Developmental brain research.
[219] A. Björklund,et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[220] Karl Kieburtz,et al. Designing neuroprotection trials in Parkinson's disease , 2003, Annals of neurology.
[221] J. Kordower. In vivo gene delivery of glial cell line–derived neurotrophic factor for Parkinson's disease , 2003, Annals of neurology.
[222] J. Milbrandt,et al. Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons , 1998, The Journal of Neuroscience.
[223] J. Loring,et al. Differentiation of neural lineage cells from human pluripotent stem cells. , 2008, Methods.
[224] Benjamin E. Reubinoff,et al. Neural progenitors from human embryonic stem cells , 2001, Nature Biotechnology.
[225] R. Barker,et al. Neurotrophic factors as a therapeutic target for Parkinson's disease , 2008, Expert opinion on therapeutic targets.
[226] J. Obeso,et al. Dopaminergic transplantation for parkinson's disease: Current status and future prospects , 2009, Annals of neurology.
[227] E. Boddeke,et al. Differentiation of non-mesencephalic neural stem cells towards dopaminergic neurons , 2010, Neuroscience.
[228] O. Isacson,et al. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. , 2008, Brain : a journal of neurology.
[229] Jiang Li,et al. Gene expression in human neural stem cells: effects of leukemia inhibitory factor , 2003, Journal of neurochemistry.
[230] A. Björklund,et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. , 2008, Brain : a journal of neurology.
[231] R. McKay,et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells , 2000, Nature Biotechnology.
[232] J. Obeso,et al. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough , 2004, The Lancet Neurology.
[233] Hansjürgen Bratzke,et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) , 2002, Journal of Neurology.
[234] M. Matsumura,et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. , 2002, Human gene therapy.
[235] A. Björklund,et al. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. , 1983, Acta physiologica Scandinavica. Supplementum.
[236] P. Aebischer,et al. Long‐term glial cell line‐derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production , 2005, Journal of neurochemistry.
[237] C. Goetz,et al. Dopaminergic Transplants in Patients with Parkinson's Disease: Neuroanatomical Correlates of Clinical Recovery , 1997, Experimental Neurology.
[238] F. Gage,et al. Intrastriatal grafting of dopamine-containing neuronal cell suspensions: effects of mixing with target or non-target cells. , 1986, Brain research.
[239] Kwang-Soo Kim,et al. The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons , 2005, Molecular and Cellular Neuroscience.
[240] C. Lundberg,et al. Lentiviral vectors for use in the central nervous system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[241] A. Björklund,et al. Characterization of Lewy body pathology in 12‐ and 16‐year‐old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[242] A. Björklund,et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. , 2005, Brain : a journal of neurology.
[243] Scott A Noggle,et al. Differentiation of Human Embryonic Stem Cells to Dopaminergic Neurons in Serum‐Free Suspension Culture , 2004, Stem cells.
[244] Langston Jw,et al. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .
[245] S. Weiss,et al. Generation of Tyrosine Hydroxylase-Producing Neurons from Precursors of the Embryonic and Adult Forebrain , 1999, The Journal of Neuroscience.
[246] A. Hebb,et al. Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage. , 2003, Neurosurgical focus.
[247] Jeffrey H Kordower,et al. Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models , 2006, Cell transplantation.
[248] G. Enikolopov,et al. The Role of Lmx1a in the Differentiation of Human Embryonic Stem Cells into Midbrain Dopamine Neurons in Culture and After Transplantation into a Parkinson's Disease Model , 2009, Stem cells.
[249] F. Horak,et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. , 2011, Archives of neurology.
[250] J. Rothwell,et al. Neural transplantation in Parkinson's disease: the Swedish experience. , 1990, Progress in brain research.
[251] H. Lester,et al. Functional characterization of dopaminergic neurons derived from rodent mesencephalic progenitor cells , 2003, Journal of Chemical Neuroanatomy.
[252] S. Yamanaka,et al. Induction of pluripotency by defined factors , 2011, Neuroscience Research.
[253] H. Gao,et al. [Neurturin: a relative of glial-cell-line-derived neurotrophic factor]. , 1998, Sheng li ke xue jin zhan [Progress in physiology].
[254] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[255] A. Lang,et al. Crossroads in GDNF therapy for Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.
[256] R. Ridley,et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus) , 2003, Experimental Neurology.
[257] K. Auguste,et al. Neural stem cells are uniquely suited for cell replacement and gene therapy in the CNS. , 2000, Novartis Foundation symposium.
[258] A. Björklund,et al. Growth and Functional Efficacy of Intrastriatal Nigral Transplants Depend on the Extent of Nigrostriatal Degeneration , 2001, The Journal of Neuroscience.
[259] G. Nikkhah,et al. Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat parkinson model , 1993, Neuroscience.
[260] A. Björklund. Cell replacement strategies for neurodegenerative disorders. , 2000, Novartis Foundation symposium.
[261] R. M. Lightfoot,et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. , 2007, Toxicologic pathology.
[262] Jia Liu,et al. How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson’s disease? , 2007, Neuroscience bulletin.
[263] R. Roth,et al. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus) , 1997, Neuroscience.
[264] Shinya Yamanaka,et al. Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors , 2008, Science.
[265] J. Langston,et al. MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. , 1984, Acta neurologica Scandinavica. Supplementum.
[266] M. Tomishima,et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling , 2009, Nature Biotechnology.
[267] A. Björklund,et al. Fetal mesencephalic neurons survive and extend long axons across peripheral nervous system grafts inserted into the adult rat striatum , 1984, Neuroscience Letters.
[268] A. Björklund,et al. Gene Therapy for Dopamine Replacement in Parkinson´s Disease , 2009, Science Translational Medicine.
[269] D. Kirik,et al. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. , 2004, Human gene therapy.
[270] M. Johnson,et al. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells , 2009, Development.
[271] Scott T. Grafton,et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. , 1990, Archives of neurology.
[272] P. Aebischer,et al. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[273] S. Rehncrona. A critical review of the current status and possible developments in brain transplantation. , 1997, Advances and technical standards in neurosurgery.
[274] S. V. Anisimov,et al. Transplantation of Human Embryonic Stem Cell‐Derived Cells to a Rat Model of Parkinson's Disease: Effect of In Vitro Differentiation on Graft Survival and Teratoma Formation , 2006, Stem cells.
[275] D. Trono,et al. A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.
[276] G. Nikkhah,et al. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[277] H. Braak,et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered , 2006, Movement disorders : official journal of the Movement Disorder Society.
[278] M. Tuszynski,et al. Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. , 2007, Parkinsonism & related disorders.
[279] Joris van Arensbergen,et al. Enhanced Yield of Neuroepithelial Precursors and Midbrain‐Like Dopaminergic Neurons from Human Embryonic Stem Cells Using the Bone Morphogenic Protein Antagonist Noggin , 2007, Stem cells.
[280] S. Iversen,et al. Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway , 1981, Brain Research.
[281] George Q. Daley,et al. Reprogramming of human somatic cells to pluripotency with defined factors , 2008, Nature.
[282] J. Bloch,et al. Lentiviral Gene Transfer to the Nonhuman Primate Brain , 1999, Experimental Neurology.
[283] D. Muruve,et al. Immune responses to adeno-associated virus vectors. , 2005, Current gene therapy.
[284] S. Haber,et al. Reversal of Parkinsonism by Fetal Nerve Cell Transplants in Primate Brain a , 1987, Annals of the New York Academy of Sciences.
[285] S. Dunnett,et al. Human stem cells for CNS repair , 2007, Cell and Tissue Research.
[286] P. Pivirotto,et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[287] Stanley Fahn,et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.
[288] J. Kordower,et al. Future of cell and gene therapies for Parkinson's disease , 2008, Annals of neurology.
[289] O. Isacson,et al. Lack of functional relevance of isolated cell damage in transplants of Parkinson’s disease patients , 2009, Journal of Neurology.
[290] Su-Chun Zhang,et al. Human Embryonic Stem Cell‐Derived Dopaminergic Neurons Reverse Functional Deficit in Parkinsonian Rats , 2008 .
[291] R. Love. Dyskinesias after transplantation in Parkinson's disease , 2002, The Lancet Neurology.
[292] D. Gash,et al. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo , 1995, Brain Research.
[293] M. Gates,et al. Stem cell-derived dopamine neurons for brain repair in Parkinson's disease. , 2010, Regenerative medicine.
[294] R. Jaenisch,et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.
[295] P. Brundin,et al. From bench to bed: the potential of stem cells for the treatment of Parkinson’s disease , 2007, Cell and Tissue Research.
[296] Markus Tolnay,et al. The propagation of prion-like protein inclusions in neurodegenerative diseases , 2010, Trends in Neurosciences.
[297] Redmond De. Cellular replacement therapy for Parkinson's disease--where we are today? , 2002 .
[298] G. Linazasoro. Rate of progression determines the clinical outcome after neural transplantation in Parkinson's disease. , 2006, Brain : a journal of neurology.
[299] J. Nutt,et al. Treatment of Parkinson’s disease with trophic factors , 2008, Neurotherapeutics.
[300] Su-Chun Zhang,et al. Directed differentiation of neural-stem cells and subtype-specific neurons from hESCs. , 2010, Methods in molecular biology.
[301] R. Bartus,et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[302] A. Björklund,et al. Intracerebral Transplantation of Dopamine Neurons: Understanding the Functional Role of the Mesolimbocortical Dopamine System and Developing a Therapy for Parkinson's Disease a , 1988, Annals of the New York Academy of Sciences.
[303] Kwang-Soo Kim,et al. Embryonic Stem Cell‐Derived Pitx3‐Enhanced Green Fluorescent Protein Midbrain Dopamine Neurons Survive Enrichment by Fluorescence‐Activated Cell Sorting and Function in an Animal Model of Parkinson's Disease , 2008, Stem cells.
[304] S. Yamanaka,et al. Induction of pluripotent stem cells from fibroblast cultures , 2007, Nature Protocols.
[305] C. Olanow,et al. The Influence of Donor Age on the Survival of Solid and Suspension Intraparenchymal Human Embryonic Nigral Grafts , 1995 .
[306] C. Olanow,et al. Neural transplantation as a therapy for Parkinson's disease. , 1997, Advances in neurology.
[307] J. Pedraz,et al. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. , 2007, International journal of pharmaceutics.
[308] M. Beal,et al. Functional engraftment of human ES cell–derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes , 2006, Nature Medicine.
[309] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[310] A. Schapira,et al. Why have we failed to achieve neuroprotection in Parkinson's disease? , 2008, Annals of neurology.
[311] F. Gage,et al. Intracerebral grafting of neuronal cell suspensions. II. Survival and growth of nigral cell suspensions implanted in different brain sites. , 1983, Acta physiologica Scandinavica. Supplementum.
[312] S. Dunnett,et al. Long-Term Survival of Human Central Nervous System Progenitor Cells Transplanted into a Rat Model of Parkinson's Disease , 1997, Experimental Neurology.
[313] M. Emborg,et al. Cell-based therapies for Parkinson's disease: past, present, and future. , 2009, Antioxidants & redox signaling.
[314] B. Hoffer,et al. Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.
[315] R. Bakay,et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.
[316] J. Kordower,et al. Lewy body pathology in long-term fetal nigral transplants: is parkinson's disease transmitted from one neural system to another? , 2009, Neuropsychopharmacology.
[317] J. Jankovic,et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.
[318] M. Cenci,et al. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[319] S. Iversen,et al. Behavioural recovery following transplantation of substantia nigra in rats subjected to 6-OHDA lesions of the nigrostriatal pathway. I. Unilateral lesions , 1981, Brain Research.
[320] A. Björklund,et al. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra , 2004, Cell and Tissue Research.
[321] O. Lindvall,et al. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. , 2009, Trends in pharmacological sciences.
[322] R. Barker,et al. The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias , 2007, Neurobiology of Disease.
[323] K. J. Child,et al. The new humanism , 1976 .
[324] V. Tabar,et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[325] A. Björklund,et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. , 2005, Brain : a journal of neurology.
[326] P. Brundin,et al. Growth Factors and Feeder Cells Promote Differentiation of Human Embryonic Stem Cells into Dopaminergic Neurons: A Novel Role for Fibroblast Growth Factor-20 , 2008, Front. Neurosci..
[327] S. Kish,et al. Dementia, parkinsonism, and motor neuron disease: Neurochemical and neuropathological correlates , 1988, Annals of neurology.
[328] Marius Wernig,et al. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells , 2007, Nature Biotechnology.
[329] S. Yamanaka. Strategies and new developments in the generation of patient-specific pluripotent stem cells. , 2007, Cell stem cell.
[330] C. Olanow,et al. Neuropathology of fetal nigral grafts in patients with Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[331] P. Remy,et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT‐PD) , 1999, Movement disorders : official journal of the Movement Disorder Society.
[332] A. Björklund,et al. Functional Activity of Substantia Nigra Grafts Reinnervating the Striatum: Neurotransmitter Metabolism and [14C]2‐Deoxy‐d‐glucose Autoradiography , 1982, Journal of neurochemistry.
[333] Monte A. Gates,et al. Site-Specific Migration and Neuronal Differentiation of Human Neural Progenitor Cells after Transplantation in the Adult Rat Brain , 1999, The Journal of Neuroscience.
[334] C. Svendsen,et al. Neurospheres modified to produce glial cell line‐derived neurotrophic factor increase the survival of transplanted dopamine neurons , 2002, Journal of neuroscience research.
[335] A. Schapira,et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial , 2006, The Lancet Neurology.
[336] O. Lindvall,et al. Clinical observations after neural transplantation in Parkinson's disease. , 2000, Progress in brain research.
[337] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[338] L. Iacovitti,et al. A protocol for the differentiation of human embryonic stem cells into dopaminergic neurons using only chemically defined human additives: Studies in vitro and in vivo , 2007, Brain Research.
[339] David Eidelberg,et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.
[340] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[341] R. McKay,et al. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats , 1998, Nature Neuroscience.
[342] R. Roth,et al. Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions , 1989, Neuroscience.
[343] L. Studer,et al. Protocols for generating ES cell-derived dopamine neurons. , 2009, Advances in experimental medicine and biology.
[344] B J Hoffer,et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. , 1989, Archives of neurology.
[345] G. Galbraith,et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state , 2008 .
[346] R. Roth,et al. Transplantation of fetal neurons in primates. , 1988, Clinical research.
[347] S. Dunnett,et al. Nigrostriatal reconstruction after 6-OHDA lesions in rats: combination of dopamine-rich nigral grafts and nigrostriatal “bridge” grafts , 2004, Experimental Brain Research.
[348] J. Kordower,et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates , 2006, Gene Therapy.
[349] H. Bradford,et al. Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: Applications in cell replacement treatment for Parkinson's disease , 2005, Progress in Neurobiology.
[350] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[351] O. Hansson,et al. Patterns of Cell Death and Dopaminergic Neuron Survival in Intrastriatal Nigral Grafts , 1999, Experimental Neurology.
[352] R. Bakay,et al. Therapeutic potentials of human embryonic stem cells in Parkinson’s disease , 2008, Neurotherapeutics.
[353] L. Holm,et al. Evolution of the GDNF Family Ligands and Receptors , 2006, Brain, Behavior and Evolution.
[354] A. Dagher,et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. , 2000, Journal of neurosurgery.
[355] M. Okun,et al. Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. , 2009, Current gene therapy.
[356] Elizabeth Hopkins Dunn,et al. Primary and secondary findings in a series of attempts to transplant cerebral cortex in the albino rat , 1917 .
[357] H. Braak,et al. Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.
[358] A. Björklund,et al. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. , 1996, Neuroscience.
[359] J. Kordower,et al. EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO‐ASSOCIATED VIRAL VECTOR TYPE 2–MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE‐120 FOR PARKINSON'S DISEASE , 2009, Neurosurgery.
[360] E. Jauniaux,et al. Human Neural Precursor Cells Express Low Levels of Telomerase in Vitro and Show Diminishing Cell Proliferation with Extensive Axonal Outgrowth following Transplantation , 2000, Experimental Neurology.
[361] Mart Saarma,et al. Novel functions and signalling pathways for GDNF , 2003, Journal of Cell Science.
[362] Zoologie. Glial Cell Line-Derived Neurotrophic Factor , 2011 .
[363] J. Fawcett,et al. Bridge grafts of fibroblast growth factor-4-secreting schwannoma cells promote functioal axonal regeneration in the nigrostriatal pathway of the adult rat , 1996, Neuroscience.
[364] Y. Agid,et al. Pathology of Symptomatic Tremors , 2008, Movement disorders : official journal of the Movement Disorder Society.
[365] E. Jauniaux,et al. Regional specification of rodent and human neurospheres. , 2002, Brain research. Developmental brain research.
[366] A. Storch,et al. Developmental Perspectives on Human Midbrain-Derived Neural Stem Cells , 2006, Neurodegenerative Diseases.
[367] O. Lindvall,et al. Human fetal cortical and striatal neural stem cells generate region‐specific neurons in vitro and differentiate extensively to neurons after intrastriatal transplantation in neonatal rats , 2006, Journal of neuroscience research.
[368] D J Brooks,et al. Delayed recovery of movement‐related cortical function in Parkinson's disease after striatal dopaminergic grafts , 2000, Annals of neurology.
[369] Guido Nikkhah,et al. Preservation of fetal ventral mesencephalic cells by cool storage: in-vitro viability and TH-positive neuron survival after microtransplantation to the striatum , 1995, Brain Research.
[370] C. Marsden,et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. , 2000, Brain : a journal of neurology.
[371] Marius Wernig,et al. In vitro differentiation of transplantable neural precursors from human embryonic stem cells , 2001, Nature Biotechnology.
[372] I. Chalmers. Letter: Obstetric Delivery Today. , 1976, Lancet.
[373] Ronald Melki,et al. Prion-like transmission of protein aggregates in neurodegenerative diseases , 2010, Nature Reviews Molecular Cell Biology.
[374] Chad A. Cowan,et al. A high-efficiency system for the generation and study of human induced pluripotent stem cells. , 2008, Cell stem cell.
[375] A. Abeliovich,et al. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[376] G. Akopian,et al. Non-human Primate Models of Parkinson's Disease and Experimental Therapeutics , 2008 .
[377] Martin Fussenegger,et al. Pharmacologic transgene control systems for gene therapy , 2006, The journal of gene medicine.
[378] F. Vingerhoets,et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease , 1995, Annals of neurology.
[379] P. Brundin,et al. Transplantation in Parkinson's disease: The future looks bright. , 2006, Advances in experimental medicine and biology.
[380] Frederick Naftolin,et al. Fetal neural graft survival , 1990, The Lancet.
[381] Bruce G. Jenkins,et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[382] Eva Hedlund,et al. Selection of Embryonic Stem Cell‐Derived Enhanced Green Fluorescent Protein‐Positive Dopamine Neurons Using the Tyrosine Hydroxylase Promoter Is Confounded by Reporter Gene Expression in Immature Cell Populations , 2007, Stem cells.
[383] Mark Stacy,et al. Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.
[384] A. Lees,et al. Striatonigral degeneration. A clinicopathological study. , 1990, Brain : a journal of neurology.
[385] T. Schallert,et al. Delivery of a GDNF Gene into the Substantia Nigra after a Progressive 6-OHDA Lesion Maintains Functional Nigrostriatal Connections , 2000, Experimental Neurology.
[386] Roger A. Barker,et al. Cell Therapy in Parkinson’s Disease , 2009 .
[387] Hideyuki Okano,et al. Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[388] W. E. Clark,et al. NEURONAL DIFFERENTIATION IN IMPLANTED FŒTAL CORTICAL TISSUE , 1940, Journal of neurology and psychiatry.
[389] R. Brownstone,et al. A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats. , 2008, Brain : a journal of neurology.
[390] Andisheh Eslamboli. Assessment of GDNF in Primate Models of Parkinson's Disease: Comparison with Human Studies , 2005, Reviews in the neurosciences.
[391] A. Kingsman,et al. Multicistronic Lentiviral Vector-Mediated Striatal Gene Transfer of Aromatic l-Amino Acid Decarboxylase, Tyrosine Hydroxylase, and GTP Cyclohydrolase I Induces Sustained Transgene Expression, Dopamine Production, and Functional Improvement in a Rat Model of Parkinson's Disease. , 2002, The Journal of Neuroscience.
[392] Marios Politis,et al. Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.
[393] J. L. Eberling,et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease , 2008, Neurology.
[394] K. Mukhida,et al. GDNF therapy for Parkinson’s disease , 2008, Expert review of neurotherapeutics.
[395] K. Blomgren,et al. Characterisation of cell damage and death in embryonic mesencephalic tissue: a study on ultrastructure, vital stains and protease activity , 2002, Neuroscience.
[396] A. Björklund,et al. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease , 1997, Neuroscience.
[397] P. Larson,et al. Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. , 2008, Neurosurgery.
[398] Mart Saarma,et al. The GDNF family: Signalling, biological functions and therapeutic value , 2002, Nature Reviews Neuroscience.
[399] K. Blomgren,et al. Both apoptosis and necrosis occur early after intracerebral grafting of ventral mesencephalic tissue : a role for protease activation , 2016 .
[400] A. Björklund,et al. Non-dopaminergic neurons in ventral mesencephalic transplants make widespread axonal connections in the host brain , 2008, Experimental Neurology.
[401] A. Björklund,et al. Can human fetal dopamine neuron grafts provide a therapy for Parkinson's disease? , 1988, Progress in brain research.
[402] O. Isacson,et al. Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease. , 2002, Progress in brain research.
[403] A. Björklund,et al. Dyskinesias following neural transplantation in Parkinson's disease , 2002, Nature Neuroscience.
[404] A. Björklund,et al. Survival and function of dissociated rat dopamine neurones grafted at different developmental stages or after being cultured in vitro. , 1988, Brain research.
[405] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[406] J. Kordower,et al. Lewy body pathology in fetal grafts , 2010, Annals of the New York Academy of Sciences.
[407] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[408] Philippe Hantraye,et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. , 2008, Current gene therapy.
[409] K. Woltjen,et al. Virus free induction of pluripotency and subsequent excision of reprogramming factors , 2009, Nature.
[410] J. Kordower,et al. Trophic factors therapy in Parkinson's disease. , 2009, Progress in brain research.
[411] Nadine Kabbani,et al. Enhanced Proliferation, Survival, and Dopaminergic Differentiation of CNS Precursors in Lowered Oxygen , 2000, The Journal of Neuroscience.
[412] H. Blau,et al. Nuclear reprogramming to a pluripotent state by three approaches , 2010, Nature.
[413] G. Gerhardt,et al. Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys , 2002, Neurobiology of Aging.
[414] R. Roth,et al. Human neural stem cells migrate along the nigrostriatal pathway in a primate model of Parkinson's disease , 2008, Experimental Neurology.
[415] A. Björklund,et al. Reinnervation of the denervated striatum by substantia nigra transplants: Functional consequences as revealed by pharmacological and sensorimotor testing , 1980, Brain Research.
[416] J. Kordower,et al. Primate models of Parkinson’s disease , 2003, Experimental Neurology.
[417] A. Björklund,et al. Cell therapy in Parkinson's disease – stop or go? , 2001, Nature Reviews Neuroscience.
[418] R. Roth,et al. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP‐treated monkeys: Feasibility relevant to multiple‐target grafting as a therapy for Parkinson's disease , 2002, The Journal of comparative neurology.
[419] J. Langston. MPTP neurotoxicity: an overview and characterization of phases of toxicity. , 1985, Life sciences.
[420] O. Hansson,et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. , 2000, Cell transplantation.
[421] B. Davidson,et al. Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy , 1997, Science.
[422] R. Barker,et al. The potential of GDNF as a treatment for Parkinson's disease , 2004, Experimental Neurology.
[423] Johannes Schwarz,et al. Long-Term Proliferation and Dopaminergic Differentiation of Human Mesencephalic Neural Precursor Cells , 2001, Experimental Neurology.
[424] A. Björklund,et al. Involvement of the serotonin system in L-dopa-induced dyskinesias. , 2008, Parkinsonism & related disorders.
[425] Anders Björklund,et al. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. , 2007, Brain : a journal of neurology.
[426] Tomas Björklund,et al. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. , 2007, Current gene therapy.
[427] A. Dagher,et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. , 2002, Journal of neurosurgery.
[428] J. Nutt,et al. GDNF in treatment of Parkinson's disease: response to editorial , 2006, The Lancet Neurology.
[429] A. Srivastava,et al. Potentials of ES cell therapy in neurodegenerative diseases. , 2008, Current pharmaceutical design.
[430] Fred H. Gage,et al. Cell culture: Progenitor cells from human brain after death , 2001, Nature.
[431] S. Gill,et al. Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.
[432] C. Hawkes. The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it? , 2008, Movement disorders : official journal of the Movement Disorder Society.
[433] R. Mandel,et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[434] A. Björklund,et al. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson’s disease , 2010, Brain : a journal of neurology.
[435] A. Björklund,et al. Intranigral Transplants of GABA-Rich Striatal Tissue Induce Behavioral Recovery in the Rat Parkinson Model and Promote the Effects Obtained by Intrastriatal Dopaminergic Transplants , 1999, Experimental Neurology.
[436] M. Hong,et al. Reconstruction of the striato-nigro-striatal circuitry by simultaneous double dopaminergic grafts: a tracer study using fluorogold and horseradish peroxidase , 1997, Brain Research.
[437] R. Hauser,et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[438] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[439] D. Trono. HIV‐based vectors: getting the best out of the worst , 2000, The journal of gene medicine.
[440] J. Milbrandt,et al. Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[441] C. Borlongan,et al. Stem cells and neurological diseases , 2007, Cell proliferation.
[442] N. Déglon,et al. Lentiviruses as vectors for CNS diseases. , 2002, Current topics in microbiology and immunology.
[443] Philippe Hantraye,et al. Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.
[444] D. Standaert,et al. Design of clinical trials of gene therapy in Parkinson disease , 2008, Experimental Neurology.
[445] L. Olson,et al. Brain tissue transplanted to the anterior chamber of the eye , 1976, Cell and Tissue Research.
[446] A. Schapira,et al. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.
[447] G. Nikkhah,et al. A microtransplantation approach for cell suspension grafting in the rat parkinson model: A detailed account of the methodology , 1994, Neuroscience.
[448] Björn Gustavii,et al. Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.
[449] B J Hoffer,et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. , 1979, Science.
[450] R. Roth,et al. AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons , 2008, Experimental Neurology.
[451] E. Snyder,et al. Human neurospheres derived from the fetal central nervous system are regionally and temporally specified but are not committed , 2006, Experimental Neurology.
[452] D. Kirik,et al. Scientific rationale for the development of gene therapy strategies for Parkinson's disease. , 2009, Biochimica et biophysica acta.
[453] A. Björklund,et al. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6‐OHDA lesion model depends on the site of administration of the trophic factor , 2000, The European journal of neuroscience.
[454] R. Bakay,et al. Preliminary report on the use of fetal tissue transplantation to correct MPTP-induced Parkinson-like syndrome in primates. , 1985, Applied neurophysiology.
[455] R. Barker,et al. Cell replacement therapy for Parkinson's disease. , 2009, Biochimica et biophysica acta.
[456] R. Hauser,et al. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.
[457] Deborah A. Ryan,et al. Translational considerations for CNS gene therapy , 2007, Expert opinion on biological therapy.
[458] C. Olanow,et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. , 1999, Archives of neurology.
[459] S. Minger,et al. Regenerative medicine in Parkinson's disease: generation of mesencephalic dopaminergic cells from embryonic stem cells. , 2005, Current opinion in biotechnology.
[460] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[461] S. Haber,et al. FETAL NEURONAL GRAFTS IN MONKEYS GIVEN METHYLPHENYLTETRAHYDROPYRIDINE , 1986, The Lancet.
[462] D. Hilt,et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. , 1997, The Journal of pharmacology and experimental therapeutics.
[463] O. Lindvall,et al. Health‐related quality of life following bilateral intrastriatal transplantation in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[464] P. Bryant,et al. Isolation and characterization of neural progenitor cells from post‐mortem human cortex , 2003, Journal of neuroscience research.
[465] A. Björklund,et al. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease , 2004, Experimental Brain Research.
[466] R. McKay,et al. In vitro generation and transplantation of precursor‐derived human dopamine neurons , 2001, Journal of neuroscience research.
[467] Hansjürgen Bratzke,et al. Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.
[468] M. Fiandaca,et al. Current status of gene therapy trials for Parkinson's disease , 2008, Experimental Neurology.
[469] R. Bakay,et al. Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration , 2002, The Journal of Neuroscience.
[470] E. Snyder,et al. Large animal models are critical for rationally advancing regenerative therapies. , 2006, Regenerative medicine.
[471] M. Emborg. Evaluation of animal models of Parkinson's disease for neuroprotective strategies , 2004, Journal of Neuroscience Methods.
[472] L. Olson,et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[473] O. Lindvall,et al. Role of cell therapy in Parkinson disease. , 2002, Neurosurgical focus.
[474] A. Björklund,et al. Cell replacement therapies for central nervous system disorders , 2000, Nature Neuroscience.
[475] Luigi Naldini,et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.
[476] M. Tomishima,et al. Efficient derivation of functional floor plate tissue from human embryonic stem cells. , 2010, Cell stem cell.
[477] J. Kordower,et al. Gene therapy for Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[478] R. Roth,et al. Embryonic Substantia Nigra Grafts Show Directional Outgrowth to Cografted Striatal Grafts and Potential for Pathway Reconstruction in Nonhuman Primate , 2008, Cell transplantation.
[479] F. Gage,et al. Isolation, characterization, and use of stem cells from the CNS. , 1995, Annual review of neuroscience.
[480] C. Svendsen,et al. Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro. , 2006, Experimental cell research.
[481] Su-Chun Zhang. Neural Subtype Specification from Embryonic Stem Cells , 2006, Brain pathology.
[482] H. Mizukami,et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease , 2002, Gene Therapy.
[483] A. Björklund,et al. Overexpression of Glial Cell Line-Derived Neurotrophic Factor Using a Lentiviral Vector Induces Time- and Dose-Dependent Downregulation of Tyrosine Hydroxylase in the Intact Nigrostriatal Dopamine System , 2004, The Journal of Neuroscience.
[484] A.C. Ramachandran,,et al. A Multiple Target Neural Transplantation Strategy for Parkinson's Disease , 2002, Reviews in the neurosciences.
[485] J. Obeso,et al. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease , 2004, Annals of neurology.
[486] P. Pivirotto,et al. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[487] D. Muruve,et al. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge , 2008, Gene Therapy.
[488] L. Olson,et al. Human fetal substantia nigra grafted to the dopamine-denervated striatum of immunosuppressed rats: evidence for functional reinnervation , 1986, Neuroscience Letters.
[489] H. Braak,et al. α-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei , 2001, Acta Neuropathologica.
[490] S. Prusiner,et al. Is Parkinson's disease a prion disorder? , 2009, Proceedings of the National Academy of Sciences.
[491] Thomas Vierbuchen,et al. Direct conversion of fibroblasts to functional neurons by defined factors , 2010, Nature.
[492] Masahiro Yamaguchi,et al. Generation of Dopaminergic Neurons in the Adult Brain from Mesencephalic Precursor Cells Labeled with a nestin-GFP Transgene , 2001, The Journal of Neuroscience.
[493] J. López-Barneo,et al. Absolute requirement of GDNF for adult catecholaminergic neuron survival , 2008, Nature Neuroscience.
[494] Timothy Sendera,et al. Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.
[495] R. Roth,et al. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. , 1990, Brain : a journal of neurology.
[496] D. Brooks,et al. Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.
[497] Maya Schuldiner,et al. Induced neuronal differentiation of human embryonic stem cells , 2001, Brain Research.
[498] O. Lindvall,et al. Research in motion: the enigma of Parkinson's disease pathology spread , 2008, Nature Reviews Neuroscience.
[499] Z. Master,et al. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson’s disease , 2007, Journal of Medical Ethics.
[500] S. V. Anisimov,et al. Fibroblast Growth Factor-20 Increases the Yield of Midbrain Dopaminergic Neurons Derived from Human Embryonic Stem Cells , 2007, Frontiers in neuroanatomy.
[501] G. Nikkhah,et al. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model , 1994, Brain Research.
[502] A. Björklund,et al. Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism. , 1993, Advances in neurology.
[503] R. Roth,et al. Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. , 1987, Life sciences.
[504] T. Iwatsubo,et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[505] Richard S. J. Frackowiak,et al. Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's disease , 1994, Annals of neurology.
[506] Scott T. Grafton,et al. Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. , 1990, Progress in brain research.
[507] Fabrizio Stocchi,et al. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.
[508] Melitta Schachner,et al. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons , 2002, Nature Biotechnology.
[509] C. Svendsen,et al. Human Neural Stem Cells: Isolation, Expansion and Transplantation , 1999, Brain pathology.
[510] O. Lindvall. Neural transplantation: can we improve the symptomatic relief? , 1999, Advances in neurology.
[511] Takashi Aoi,et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts , 2008, Nature Biotechnology.
[512] K. Auguste,et al. Global gene and cell replacement strategies via stem cells , 2002, Gene Therapy.
[513] S. Dunnett,et al. Potential cellular and regenerative approaches for the treatment of Parkinson’s disease , 2008, Neuropsychiatric disease and treatment.
[514] C. Svendsen,et al. GDNF-Secreting Human Neural Progenitor Cells Increase Tyrosine Hydroxylase and VMAT2 Expression in MPTP-Treated Cynomolgus Monkeys , 2008, Cell transplantation.
[515] Wenjun Guo,et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2 , 2008, Nature Biotechnology.
[516] G. Gerhardt,et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.